Cytokinetics, Inc.
626 articles about Cytokinetics, Inc.
-
The FDA is expected to cap off February with a trio of verdicts, including one for a heart failure treatment and another potential first approval for a rare, neurodegenerative disease.
-
Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
2/24/2023
Cytokinetics, Incorporated announced three poster presentations at the American College of Cardiology 72nd Annual Scientific Session taking place in New Orleans, LA from March 4, 2023 – March 6, 2023.
-
Cytokinetics to Announce Fourth Quarter Results on March 1, 2023
2/15/2023
Cytokinetics, Incorporated announced that it is scheduled to report fourth quarter results on March 1, 2023 at 4:00 PM Eastern Time.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2023
2/1/2023
Cytokinetics, Incorporated announced that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to their employment.
-
Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant ProgramTotal of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach
1/30/2023
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fifth annual Communications Grant Program, intended to support communications, awareness building and community engagement for nonprofit organizations serving the patient community.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023
1/4/2023
Cytokinetics, Incorporated announced that on December 30, 2022 it granted stock options to purchase an aggregate of 130,000 shares of common stock to 6 new employees, whose employment commenced in December 2022, as a material inducement to their employment.
-
Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 AM Pacific Time at the Westin St. Francis Hotel in San Francisco.
-
The FDA’s Cardiovascular and Renal Drugs Advisory Committee stood against Cytokinetics, Inc., finding that the benefits of its heart failure hopeful didn’t outweigh its risks.
-
Cytokinetics Stock Trading Halted Today
12/13/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Nasdaq has halted the trading of the Company’s common stock.
-
Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
12/13/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF).
-
Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil
12/9/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug Application (NDA) for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).
-
Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND
12/8/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data were presented at the Virtual 33rd International Symposium on ALS/MND related to survival predictions from FORTITUDE-ALS.
-
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility
12/7/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of CK-3828136 (CK-136), formerly known as AMG 594.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022
12/2/2022
Cytokinetics, Incorporated announced that on November 30, 2022 it granted stock options to purchase an aggregate of 146,100 shares of common stock to 14 new employees, whose employment commenced in November 2022, as a material inducement to their employment.
-
Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND
12/1/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33rd International Symposium on ALS/MND taking place online from December 6, 2022 - December 9, 2022 relating to survival predictions from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS.
-
Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022
11/7/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF as well as an analysis of patients hospitalized for heart failure with reduced ejection fraction.
-
Cytokinetics Reports Third Quarter 2022 Financial Results
11/3/2022
Cytokinetics, Incorporated reported financial results for the third quarter of 2022.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022
11/1/2022
Cytokinetics, Incorporated announced that on October 31, 2022 it granted stock options to purchase an aggregate of 202,500 shares of common stock to 20 new employees, whose employment commenced in October 2022, as a material inducement to their employment.
-
Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022
10/31/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association Scientific Sessions 2022 taking place in Chicago, IL from November 5, 2022 - November 7, 2022.
-
Cytokinetics to Announce Third Quarter Results on November 3, 2022
10/20/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2022 at 4:00 PM Eastern Time.